A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-Overexpressing Metastatic Breast Cancer.

Trial Profile

A Phase Ib Study Investigating the Combination of Everolimus With Trastuzumab and Vinorelbine in Patients With HER2-Overexpressing Metastatic Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Everolimus (Primary) ; Trastuzumab; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 06 Oct 2011 Actual end date (1 Jun 2010) added as reported by ClinicalTrials.gov.
    • 06 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top